RESUMO
AIM: The present research work was undertaken to describe various clinical signs and hematobiochemical alterations in dogs affected with Babesia gibsoni. MATERIALS AND METHODS: Blood smears from a total of 79 suspected dogs of Anand region as well as Surat region of Gujarat state (India) were screened for detection of intraerythrocytic piroplasm of small form of Babesia. Diagnosis was made on the basis of clinical signs and demonstration of B. gibsoni organism in Giemsa-stained thin blood smears. The clinical signs were recorded at the time of presentation, and blood samples were subjected to estimation of hematobiochemical parameters by auto hematology analyzers at College of Veterinary Science and Animal Husbandry, Anand. Statistical analysis, interpretation, and comparison of hematobiochemical changes with scientific literature were carried out to understand the pathophysiology of the disease. RESULTS: Out of 79 dogs, 16 were positive for naturally occurring babesiosis based on the presence of intraerythrocytic piroplasm of small form of Babesia in blood smears. The clinical cases were manifested by wide variety of non-specific clinical signs. The hematological evaluation revealed that the mean values of hemoglobin and total erythrocyte counts in dogs with babesiosis decreased significantly (p<0.01) in comparison to healthy dogs. Among differential leukocyte count, mean values of neutrophils and eosinophils increased while lymphocytes decreased (p<0.01) in dogs with babesiosis in comparison to healthy dogs. Serum biochemistry revealed increase (p<0.01) value of alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, and globulin as well as decrease in albumin levels (p<0.05) in dogs with babesiosis as compared to healthy dogs. CONCLUSION: B. gibsoni is having multisystemic effects with atypical hematobiochemical changes in dog are discussed here, which would aid new insights in diagnosis of disease.
RESUMO
A stability-indicating reverse phase high performance liquid chromatography method was developed and validated for cefixime and linezolid. The wavelength selected for quantitation was 276 nm. The method has been validated for linearity, accuracy, precision, robustness, limit of detection and limit of quantitation. Linearity was observed in the concentration range of 2-12 µg/ml for cefixime and 6-36 µg/ml for linezolid. For RP-HPLC, the separation was achieved by Phenomenex Luna C18 (250×4.6 mm) 5 µm column using phosphate buffer (pH 7):methanol (60:40 v/v) as mobile phase with flow rate 1 ml/min. The retention time of cefixime and linezolid were found to be 3.127 min and 11.986 min, respectively. During force degradation, drug product was exposed to hydrolysis (acid and base hydrolysis), H2O2, thermal degradation and photo degradation. The % degradation was found to be 10 to 20% for both cefixime and linezolid in the given condition. The method specifically estimates both the drugs in presence of all the degradants generated during forced degradation study. The developed methods were simple, specific and economic, which can be used for simultaneous estimation of cefixime and linezolid in tablet dosage form.